Management

He founded ZK Cancer Research biotechnological company in 2021 for which now he serves as the President and CEO. This family-owned company is based, for the most part, on his extensive research showing that an organic heterocyclic compound and some of its derivatives, all inhibiting choline transport into cancer cells, can effectively prevent the loss of body weight and skeletal muscle proteins in various cachectic mouse tumor models.

*About the Founder: Zoltan Kiss, Ph.D., had an extensive academic research career before founding and leading several biotechnological companies. Until 2004, he was Professor and Section Leader at the University of Minnesota. Prior to that, he was a Senior Investigator at the National Cancer Institute (4 years) and held several faculty positions in the U.S. and Europe. Dr. Kiss holds a Ph.D. degree, and his research so far has resulted in 114 peer-reviewed articles and 27 issued international patents as well as 5 filed patent applications on the treatments of cancer cachexia, wounds, bone marrow protection, and various metabolic disorders including specific treatment of excess visceral fat. Most recently, Dr. Kiss has been focusing on (1) studying a human protein and various heterocyclic compounds to prevent or reduce cancer cachexia, and (b) finding effective interventions to normalize excess visceral obesity and determining the nature of relationships between visceral fat as well as various metabolic disorders, cancer, and longevity in appropriate mouse models.